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AbstrACt
Objectives Population statistics for carotid plaque and 
cardiovascular risk factors reported in scientific journals 
are usually presented as averages for the population or 
age and sex adjusted, rather than sex and age groups. 
Important population differences about atherosclerosis 
and cardiovascular risk factors may thus be missed. We 
compare the distribution of cardiovascular risk factors, 
carotids plaque and carotid intima-media thickness 
(CIMT) in two population-based studies.
Methods Carotid artery atherosclerotic plaque 
prevalence and risk factors levels for cardiovascular 
disease by sex in 5-year age groups from the Risk 
Evaluation For Infarct Estimates Reykjavik study 
(REFINE-Reykjavik study) were compared with data from 
the Tromsø 6 study.
results The threshold of carotid plaque presence in 
the Tromsø 6 study fell between minimal and moderate 
plaque defined in the REFINE-Reykjavik study reflecting 
carotid plaque prevalence. The prevalence of minimal 
carotid plaque in the REFINE-Reykjavik study was 
47% in men (40–69 years old) and 38% in women 
and 11% in men and 7% in women of moderate 
plaque. The prevalence of any plaque in the Tromsø 
6 study was 35% in men and 27% in women. The 
mean (CIMT) was similar in the studies. In the Tromsø 
6 study mean systolic blood pressure was 8 mm Hg 
higher in men and 10 mm Hg higher in women, mean 
low-density lipoprotein was 0.5 mmol/L higher in men 
and 0.3 mmol/L higher in women and the prevalence 
of smoking was 4% higher in men and 9% higher in 
women. However, body mass index was 0.8 kg/m2 
higher in men and 0.9 kg/m2 in women in the REFINE-
Reykjavik study.
Conclusion Comparison between Iceland and Norway 
revealed differences in the prevalence of carotid plaque, 
which was assumed to be due to different definition 
of plaque. However, clinically significant differences in 
conventional cardiovascular risk factors were seen. This 
underscores the importance of detailed comparison of 
population data across different populations.
IntrOduCtIOn 
The value of comparing risk factors of cardio-
vascular disease between populations is undis-
puted. The Seven Countries Study and the 
WHO-led Monitoring Trends and Determi-
nants in Cardiovascular Disease (MONICA) 
Project are examples of studies that have 
monitored changes in risk factors and 
compared diets and lifestyles between coun-
tries. These studies contributed to knowledge, 
which led to changes in risk factor levels and 
the drop seen in the prevalence of coronary 
heart disease in the last decades of the 20th 
century.1 2 However, detailed information on 
the presence of atherosclerotic plaque in the 
carotid arteries across different populations 
is not readily available in the current litera-
ture. Population statistics for carotid plaque 
and for cardiovascular risk factors reported 
in scientific journals are usually presented 
as an average for the population or adjusted 
for age and sex, rather than being reported 
by different sex and age groups. Thereby, 
significant sex and age interaction in the 
strengths and limitations of this study
 ► The strength of this study is the random popula-
tion design of both the  Risk Evaluation For Infarct 
Estimates Reykjavik study  (REFINE-Reykjavik study) 
and the Tromsø 6 study.
 ► The rigid protocols of the two studies regarding 
data gathering and quality control and that the stud-
ies were conducted at similar time interval is also 
strength.
 ► The main limitation of the study are differences in 
carotid ultrasound protocols between the REFINE-
Reykjavik study and Tromsø 6 study. The study was 
done on Caucasian participants only.
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development in atherosclerosis and/or in cardiovascular 
risk factors can be missed in comparison across different 
populations based on published data. For carotid plaque, 
which is one of the best studied markers of subclinical 
atherosclerosis, different definitions of carotid plaque 
between studies also complicate the comparison.
We now publish results from the first phase of the 
Risk Evaluation For Infarct Estimates Reykjavik study 
(REFINE-Reykjavik study), which started in December 
2005 and completed in March 2011. The REFINE-Reyk-
javik study is a prospective cohort study on risk factors 
and aetiology of atherosclerotic disease in the population 
of the Reykjavik area in Iceland. The study was performed 
on a large number (6661) of individuals (25–69 years of 
age) with ultrasound of the carotids and other measure-
ments of both traditional risk factors and new risk factors 
for cardiovascular disease. The aim of REFINE-Reykjavik 
study was to demonstrate what characterises individuals 
who develop atherosclerosis and to understand if carotid 
plaque or other factors measured in the study increase 
the accuracy of risk estimates for cardiovascular disease.
The population distribution of cardiovascular risk 
factors and the prevalence of atherosclerotic plaque in 
the common carotid arteries are presented in adults living 
in the greater Reykjavik area according to age groups and 
sex. We report the data in this detailed manner in order 
to make comparisons with other studies easier and more 
accessible. We also make direct comparison between 
results from the REFINE-Reykjavik study and the Tromsø 
6 study and discuss the results in context with available 
outcomes from other population studies in Europe and 
USA. The two population studies, the REFINE-Reykjavik 
study and the Tromsø 6 study, were conducted within the 
similar time interval (REFINE-Reykjavik study: 2006–2011; 
Tromsø 6: 2007–2008), which included both genders and 
both included middle-aged participants, mostly of Scandi-
navian origin and are therefore highly comparable.
MethOds
study population
The cohort in the first phase of the REFINE-Reykjavik 
study was a random sample of 9.480 men and women 
born in 1935–1985, living in Reykjavik in November in 
the year 2005 and with Icelandic citizenship. The cohort 
was divided into 5-year age groups from 25 to 69 years. 
The age distribution was designed to over-represent 
middle-aged individuals in order to concentrate the 
power of the study on the age span where development 
of atherosclerosis was to be most expected. In the age 
groups 25–34 years, the number of individuals in each 
age group was 600, in the age groups from 35–64, the 
number was 1200 in each group and in the age group 
65–69 years, the number of individuals was 480. The 
cohort in the REFINE-Reykjavik study was drawn from 
the same geographic area as the well-established Reyk-
javik study. The cohort in the Reykjavik study included 
individuals born in 1907–1935.3 The birth year bracket in 
the REFINE-Reykjavik study (1935–1985) is therefore in 
continuation of the Reykjavik study.
The cohort in REFINE-Reykjavik study is homogenous with 
the vast majority being of Scandinavian origin. Icelanders 
are genetically similar to other northern European coun-
tries,4 and risk of coronary heart disease and the contribu-
tion of the conventional risk factors to this risk is similar.5 In 
the final survey of the WHO MONICA Project conducted in 
1992, of the 38 population investigated for coronary event 
rate in men, the Icelandic population was approximately in 
the middle. Twenty populations had higher coronary event 
rate, and 17 populations had lower coronary event rate than 
the Icelandic population.6 For comparison of both conven-
tional risk factors for coronary heart disease, prevalence of 
carotid plaque and the level of CIMT in the population, data 
from Tromsø 6 study were used.
The Tromsø study is an ongoing population-based 
cohort study in the municipality of Tromsø, Northern 
Norway, with a population of 72 000 inhabitants. The 
Tromsø 6 study was conducted in the years 2007–2008. 
The age span was 40–87 years. Invited to Tromsø 6 first 
visit were all residents aged 40–42 years and 60–87 years 
(n=12 578), a 10% random sample of individuals aged 
30–39 years (n=1056), a 40% random sample of individ-
uals aged 43–59 years (n=5787) and subjects who had 
attended the second visit of Tromsø 4, if not already 
included in the three groups above (n=341). The atten-
dance rate was 66%.
Detailed description on recruitment methods, use 
of medication and supplements, clinic examination, 
blood analyses, quality control of the ultrasound of the 
carotid arteries in the REFINE-Reykjavik study is shown in 
online supplementary text 1, and description of Tromsø 
6 is available in online supplementary text 2.
ultrasound of the carotid arteries
In the REFINE-Reykjavik study, the ultrasound of the 
carotid arteries was performed using a standardised 
scanning and analysis protocol for quantitative assess-
ment of the common carotid intima-media thickness 
(IMT) and arterial stiffness. The protocol also included 
scans for semiquantitative assessment of plaque pres-
ence/absence and plaque severity. The protocol was 
developed by experts from the Vascular Imaging 
Center, Julius Center for Health Care and Primary Care 
in the University of Utrecht in the Netherlands (MLB). 
The technicians who performed the ultrasound studies 
were trained by the same experts that developed the 
protocol.
The carotid arteries on both sides were imaged from 
four different interrogation angles with 30° increments 
using a Sequoia C256, Acuson ultrasound system (Siemens 
Medical Systems, Erlangen, Germany) with an 8.0 MHz 
transducer. To standardise and control the interroga-
tion angles, the Meijers Carotid Arc was used.7 The IMT 
measurements were quantified on a predefined segment 
in near and far wall of the carotid common arteries8 using 
the Artery Measurement Software (AMS) II V.1.131.
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Outcome parameters
Common carotid IMT
B-mode images of the IMT are acquired for the predefined 
10 mm segment of each common carotid artery8 (right 
and left) at defined interrogation angles using Meijers 
Arc. Standard images are obtained from four angles at 
each site. The mean IMT of the near (shallower) and 
far (deeper) walls are determined from a single image 
at each interrogation angle for both the right and left 
common carotid arteries CCA. The average of all these 
IMT values comprised the mean IMT outcome param-
eter. The maximum IMT corresponded to the highest 
measured IMT value at the four angles.
Atherosclerotic plaque in the carotid bifurcation and internal 
carotid artery
Of the left and right carotid bifurcation and internal 
carotid artery, the presence of atherosclerotic lesions is 
measured on line, that is, during the ultrasound exam-
ination. The most severe lesion per segment is assessed in 
a semiquantitative manner. The plaque image interpreta-
tion is based on the following four categories:
1. None: complete absence of plaque, IMT thickening 
may be observed.
2. Minimal: small isolated thickening, unifocal or multi-
focal, often with calcification approximately two times 
the adjacent normal IMT.
3. Moderate: clear, reasonably easy to visualise plaque 
with or without calcification. May be located on both 
near and far wall in the segment causing some diame-
ter reduction.
4. Severe: significant plaque formation very easy to image 
with or without calcifications and visualised on several 
different scan projections in near and far wall causing 
clear diameter reduction.
Images of observed plaques were stored.
In the Tromsø 6 study, high-resolution B-mode ultraso-
nography was performed with GE Vivid 7 duplex scanners 
with linear 12 MHz transducers. The ultrasonographers 
were blinded to laboratory and clinical data. Subjects 
were examined in the supine position with the head 
slightly tilted to the left side. The sonographers were 
instructed to view the arteries from all possible angles, in 
order to find the optimal view for visualisation of plaque 
and IMT in each subject. No fixed angle of insonation 
was used. Measurements of plaque and IMT were anal-
ysed offline with the semiautomated AMS software. A 
plaque was defined as a localised protrusion into the 
vessel lumen of more than 50% thickening compared 
with the adjacent IMT. Six locations were scanned for the 
presence of plaques, the far and near walls of the right 
common carotid artery, bifurcation and internal carotid 
artery. ECG-triggered uptakes of IMT were obtained 
from the distal 10 mm segment of the far and near wall 
of the common carotid artery and of the proximal 10 mm 
segment of the far wall of the carotid bifurcation. Plaques 
were included in the IMT measurements if present in the 
predefined location of interest. The mean IMT from the 
three preselected images was calculated for each loca-
tion, and the average of the mean IMT from the three 
locations was used in the analyses. The interobserver and 
intraobserver and interequipment reproducibility of IMT 
and plaque measurements was acceptable.9–11
stAtIstICAl MethOds
Age-standardised means and proportions were presented 
and compared between the REFINE-Reykjavik and the 
Tromsø 6 study. The following risk factors were investi-
gated: systolic blood pressure, low density lipoprotein, 
body mass index (BMI), prevalence of type 2 diabetes, 
cholesterol-lowering medications (statins), hypertension 
medication, smoking, self-reported history of coronary 
heart disease, IMT and plaque in the right carotids.
Age standardisation was done according to the direct 
method, using the standard population age structure as 
defined by the European Standard Population.12 Statis-
tical significance between study summary estimates was 
investigated using linear regression for continuous vari-
ables and logistic regression for categorical variables. 
Regressions were run separately for each sex and adjusted 
for age.
IMT and prevalence of plaque in right carotids was 
presented visually by sex, age groups and study. Blood pres-
sure measurements in the REFINE-Reykjavik study were 
done using arterial tonometry,13 whereas an electronic 
sphygmomanometer (Dinamap ProCare 300 monitor, 
GE Healthcare) was used in Tromsø 6 study. A set of 
approximately 400 available and concurrently measured 
sphygmomanometer readings in REFINE-Reykjavik study 
were compared with tonometry measurements using a 
linear mixed effects model, accounting for an inherent 
repeated measures aspect. Age-specific,sex-specific and 
method-specific predicted values were used to obtain a 
correction factor, which was applied to the tonometry 
measurements in REFINE, in an effort to make them 
comparable with the Tromsø 6 study measurements.
Statistical analysis was done using Stata V.14.1.14
results
Recruitment for the REFINE-Reykjavik study started in 
December 2005 and was completed in March 2011. The 
total number of individuals who participated in the study 
was 6661—3277 men and 3384 women. The recruit-
ment rate was 73%. The sex ratio was 49% men and 51% 
women. The mean age was 49.8 years (SD 11.2 years), and 
the age range was 25–69 years.
The mean BMI for men was 27.7 (SD 4.3) kg/m2 and 
26.7 (SD 5.3) kg/m2 for women. Mean BMI was above 
25 kg/m2 in both sexes, which is the upper limit of ideal 
weight according to WHO expert committee report.15 
BMI increased with increasing age (online supplement 3 
table 1a).
Both systolic and diastolic blood pressures rose with age, 
but there was a decrease in the diastolic blood pressure 
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in the oldest age group (65–69 years old) in both sexes. 
Average systolic blood pressure in men was 125.5 mm Hg 
(SD 13.9) and 115.5 mm Hg (SD 13.7) for women, 
and average diastolic blood pressure was 70.7 mm Hg 
(SD 10.0) and 68.7 mm Hg (SD 9.0), respectively (online 
supplement 3 table 1a).
A steady increase in total cholesterol (TC), low-den-
sity lipoprotein (LDL) and triglycerides was observed in 
women with increasing age. In men, TC, LDL and TG 
peaked in middle age, decreasing again over the age of 
60 years. HDL cholesterol increased with age in both 
sexes (online supplement 3 table 1b).
Family history of myocardial infarction increased with 
age and was somewhat higher in men than women (online 
supplement 3 table 2a). History of cardiovascular disease 
and history of coronary heart disease was rare in partici-
pants younger than 50 years old but increased sharply with 
age in men, and it was 22.9% and 20.4%, respectively, in 
65–69 years old men (online supplement 3 table 2b). The 
increase was more gradually in women, history of cardio-
vascular disease and history of coronary heart disease was 
6.0% and 4.3%, respectively, in 65–69 years old women 
(online supplement 3 table 2a).
The prevalence of diabetes type 2 in men on average 
was 6% and age adjusted was 4.3%. The prevalence is 
lower in women than in men or 3% and age adjusted 
2.4%. The prevalence of diabetes increased with age in 
both sexes (online supplement 3 table 2b).
Hypertension was rare among young women 
(25–29 years), but 10% of young men had hyperten-
sion. With increasing age, the prevalence of hyperten-
sion increased sharply so that in the oldest age group 
(65–69 years), the majority of men (71%) and more than 
half of the women were hypertensive (online supplement 
3 table 2b)
Use of blood pressure-lowering drugs and cholester-
ol-lowering drugs (statins) is shown in online supple-
ment 3 table 2b. Drug treatment increased with age and 
was highest in the oldest age group. In the age group 
65–69 years, 57.1% men and 51.4% women were on treat-
ment against high blood pressure, and 33.8% of men and 
18.4% of women were treated with statins (online supple-
ment 3 table 2b).
Current smoking was highest in the age group 
25–29 years in both men (28.8%) and women (27.4%). 
The prevalence of current smoking decreases with 
increasing age. On average, 23% of men and 22% of 
women smoked (online supplement 3 table 3a).
Overweight, defined as BMI ≥25, was very common in 
men (73%) and in women (56%), and obesity, defined as 
BMI ≥30, was seen in 25% of men and 22% of women 
(online supplement 3 table 3a).
About 14% of men and women had cholesterol levels 
above 6.2 mmol/L (online supplement 3 table 3b).
Physical activity was assessed by the following ques-
tion in the health history questionnaire: ‘In the past 
12 months, how often did you participate in moderate 
or vigorous physical activity (Examples of moderate 
or vigorous physical activity include badminton. golf 
(walking), biking, swimming, heavy gardening, weight 
lifting, hiking/mountain climbing, fast walking/fast 
dancing/heavy housework, rowing, aerobics, jogging and 
running)’. About 60%–70% of men and women partici-
pated in at least moderate physical activity for 1–3 hours 
a week, and 30%–40% were active 4–7 hours a week. No 
clear difference in physical activity was seen between men 
and women or different age groups (online supplement 
3 table 3b).
In online supplement 3 table 4a, mean common CIMT 
values are shown according to age and sex. The mean 
CIMT was 0.71 mm (SD 0.10) in men and 0.67 mm (SD 
0.08) in women. CIMT increased steadily with increasing 
age in both sexes and was slightly higher in men 
than in women. For example, in the oldest age group 
(65–69 years), the mean CIMT was 0.91 mm (SD 1.3) in 
men but 0.85 (SD 0.11) mm in women. Results from the 
maximum IMT thickness are also shown in online supple-
ment 3 table 4a. Maximum IMT values increased similarly 
with age, and the sex difference was similar.
The prevalence of carotid plaque increased with age 
in both sexes (online supplement 3 table 4b).  The prev-
alence was somewhat higher in men than women at all 
ages although the sex difference was small. For example, 
7.7% of men aged 50–54 years had moderate plaque 
compared with 5.3% of women. Severe plaque or semi-
occlusion was never detected in the younger partici-
pants but was detected in 4.8% and 5.0% in the oldest 
women and men, respectively. In the youngest age group 
(25–29 years), 94.2% of men and 96.5% of the youngest 
women had no plaques, while this was seen in only 15.6% 
of the oldest men (65–69 years) and 21.6% of the oldest 
women (online  supplement 3 table 4b).
Table 1 shows the characteristics of the REFINE-Reyk-
javik study and the Tromsø 6 study in men and women 
aged 40–69 years.
The systolic blood pressure was 8 mm Hg higher in men 
and 10 mm Hg higher in women in the Tromsø 6 study than 
the REFINE-Reykjavik study. Participants in REFINE-Reyk-
javik study were more often taking antihypertensive medica-
tion than in the Tromsø 6 study (30% vs 18% in men and 
28% vs 17% in women). Calculated LDL cholesterol was 
somewhat higher in both men and women in the Tromsø 6 
study than in REFINE-Reykjavik study (0.5 mmol/L in men 
and 0.3 mmol/L in women). The prevalence of statin use 
was similar in the two studies, although somewhat more men 
were taking statins in REFINE-Reykjavik study than Tromsø 6 
study (16% vs 13%) but less women (7% vs 9%). Smoking was 
less prevalent in REFINE-Reykjavik study than the Tromsø 6 
study in both sexes, but BMI was nearly one unit higher in 
the REFINE-Reykjavik study in both sexes. The prevalence of 
type 2 diabetes was similar in men in both studies (7.4%) but 
was lower in women in the REFINE-Reykjavik study (3.9% vs 
4.9%). The mean far wall CIMT in men was 0.02 mm thicker 
in the Tromsø 6 study than the REFINE-Reykjavik study (p 
value <0.05) and 0.01 mm thicker in women (not signifi-
cant) (table 1). The prevalence of minimal or more right 
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site carotid plaque was higher in the REFINE-Reykjavik study 
than any or more right site plaque, in the Tromsø 6 study in 
both men and women. The changes in in cardiovascular risk 
factors by age was similar in both sexes and across age groups 
as is shown in online supplement 4 figure 1. 
The mean far wall CIMT increased with age as can be 
seen in figure 1. The CIMT was higher in the age group 
40–49 years in the Tromsø 6 study but was similar in the two 
studies after the age of 50 years in both men and women 
(figure 1).
As shown in figure 2, the prevalence curve for any right 
carotid plaques in the Tromsø 6 study lies between the prev-
alence curve for minimal or more carotid plaque and the 
prevalence curve for moderate or more carotid plaque in 
the REFINE-Reykjavik study (figure 2).
dIsCussIOn
In this paper, we present the average prevalence of 
atherosclerotic plaque in the carotid arteries and average 
of cardiovascular risk factors in adult population of 
Reykjavik area in Iceland in the REFINE-Reykjavik study. 
We put the results in context with the results from the 
Tromsø 6 study. The main findings are that the evidence 
of manifest atherosclerosis, that is, the prevalence of 
carotid plaques, is similar in the two studies. Systolic 
blood pressure and LDL cholesterol levels were higher 
in the Tromsø 6 study, but the mean BMI was higher in 
the REFINE-Reykjavik study. The main limitation of the 
study is the methodological difference in the definition of 
atherosclerotic plaque in the carotids arteries as further 
discussed below.
The two population studies, the REFINE-Reykjavik 
study and the Tromsø 6 study, were conducted within 
the similar time interval (REFINE-Reykjavik study: 
2006–2011, Tromsø 6: 2007–2008), which included both 
genders and both included middle-aged participants, 
mostly of Scandinavian origin and are therefore highly 
comparable. The prevalence curve for any carotid plaque 
by age and sex in the Tromsø 6 study lies in between the 
prevalence of minimal plaque and moderate plaque in the 
Table 1 Age standardised characteristic of participants in the REFINE-Reykjavik study and the Tromsø 6 study†
Men aged 40–69 years Women aged 40–69 years
REFINE-
Reykjavik (n=2629) Tromsø 6 (n=2214) Difference
REFINE-
Reykjavik (n=2719)
Tromsø 
6 (n=2981) Difference
Mean crude age (years)
(SD)
54 (8.2) 59 (5.7) −5 54 (8.2) 59 (6.1) −5
Systolic BP‡ (mm Hg)
(SD)
130 (15.5) 138 (17.7) −8** 123 (15.5) 133 (21.4) −10**
LDL (mmol/L)
(SD)
3.3 (0.9) 3.8 (0.9) −0.5** 3.3 (0.9) 3.6 (0.9) −0.3**
BMI (kg/m2)
(SD)
28.4 (4.4) 27.6 (3.7) 0.8** 27.3 (5.3) 26.4 (4.7) 0.9**
CIMT§ mean far wall 
(mm) (SD)
0.77 (0.12) 0.79 (0.15) −0.02* 0.72 (0.10) 0.73 (0.12) −0.01
Current smoker, %
(number)
21 (549) 25 (537) −4** 20 (558) 29 (777) −9
HTMED¶ users, %
(number)
30 (776) 18 (532) 12** 28 (759) 17 (690) 11**
Statin users, %
(number)
16 (410) 13 (401) 3* 7 (192) 9 (425) −2*
Known heart attack and/or 
angina††, %, (number)
8.4 (218) 7.7 (212) 0.7* 3.4 (93) 2.5 (119) 0.9
Type 2 diabetes, %
(number)
7.4 (196) 7.4 (204) 0.0 3.4 (90) 4.9 (186) −1.5**
Plaque R-carotid:
REF min, Tromsø-any, %
(number)
46.8 (1238) 35.3 (997) 11.5** 38.3 (1039) 26.6 (1042) 11.7**
*P value <0.05; **p value <0.001.
†Values are mean (SD) or percentage (number). Age standardised according to the European Standard Population 2013.
‡The REFINE-Reykjavik study blood pressure (BP) measurement were adjusted for difference between measurements from arterial 
tonometry and sphygmomanometer measurements (see methods).
§Common carotid intima-media thickness.
¶Hypertensive medication.
††According to health questionnaire.
BMI, body mass index; LDL, low-density lipoprotein; REFINE-Reykjavik, Risk Evaluation For Infarct Estimates Reykjavik study.
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REFINE-Reykjavik study for both men and women. This 
can be seen in all age groups, and the increase with age is 
similar. The difference in prevalence of carotid plaque in 
the two studies is most likely due to a different definition 
of carotid plaque. In the REFINE-Reykjavik study, minimal 
plaque was defined as a small isolated thickening unifocal 
or multifocal, often with calcification approximately two 
times the adjacent normal CIMT. A moderate plaque was 
Figure 1 Mean far wall carotid intima-media thickness in the REFINE-Reykjavik study and Tromsø 6 study by age and 
sex. REFINE-Reykjavik, Risk Evaluation For Infarct Estimates Reykjavik.
Figure 2 Prevalence of right carotid plaque in the REFINE-Reykjavik study and in the Tromsø 6 study by age and sex. REFINE-
Reykjavik, Risk Evaluation For Infarct Estimates Reykjavik. 
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defined as a clear, reasonably easily visualised plaque with 
or without calcifications that may be located on both near 
and far wall in the segment causing some diameter reduc-
tion. The definition of plaque presence in the Tromsø 6 
study was of a ‘… localized protrusion of the vessel wall 
into the lumen’.16 Focal calcifications without focal thick-
ening or protrusion into the lumen were not regarded 
as atherosclerotic plaque in the Tromsø 6 study.16 Since 
both studies show similar increase in plaque prevalence 
with increasing age and the threshold for definition 
of carotid plaque in the Tromsø 6 study seems to lie in 
between the definition for minimal and moderate plaque 
in the REFINE-Reykjavik study, we assume that the differ-
ences in plaque prevalence are mainly due to different 
definitions of plaque, although difference in prevalence 
of plaque cannot be excluded.
Comparison of the mean far wall CIMT between the 
REFINE-Reykjavik study and the Tromsø 6 study revealed 
close similarity between the two studies after the age of 
50 years. The mean CIMT was higher in the Tromsø 6 
study in participants under the age of 50 years than in 
the REFINE-Reykjavik study. However, the number of 
participants in this age group in the Tromsø 6 was rela-
tively smaller compared with older age groups, and the 
CIs for the CIMT measurements were wider. We therefore 
concluded that the mean far wall CIMT was similar in the 
REFINE-Reykjavik study and the Tromsø 6.
It is clear that the need for a standardised definition of 
plaque and CIMT is important both for clinical practice, 
in order to increase the availability of ultrasound labora-
tories that can perform high-quality carotid plaque and 
CIMT evaluation and to increase comparability between 
future studies. Both in Europe and the USA attempts have 
been made in that regard. In 2008, the American Society 
of Echocardiography Carotid Intima-Media Thickness 
Task Force published a consensus statement.17 There, 
carotid plaque was defined as ‘the presence of focal wall 
thickening that is at least 50% greater than that of the 
surrounding vessel wall or as a focal region with CIMT 
greater than 1.5 mm that protrudes into the lumen that is 
distinct from the adjacent boundary’ .17 In 2012, the Mann-
heim carotid IMT and plaque consensus (2004–2006–
2011) was published where carotid plaque was ‘defined as 
a focal structure that encroaches into the arterial lumen 
of at least 0.5 mm or 50% of the surrounding IMT value 
or demonstrates a thickness >1.5 mm as measured from 
the media-adventitia interface to the intima-lumen inter-
face’.18 These two consensus statements give very similar 
definitions of plaque and will hopefully reduce confusion 
that different definitions can cause.
In all age groups, except for women aged 25–29 years, 
the mean BMI value was over 25 kg/m2, the upper limit 
of normal weight according to WHO definition19 .In 
the REFINE-Reykjavik study the mean BMI value for 
women was 26.7 kg/m2 and for men 28.7 kg/m2. More 
than a third of men over the age of 50 years were obese 
according to the WHO definition. In the Organisation 
for Economic Co-operation and Development (OECD) 
report ‘Obesity update 2017’, it is stated that, on average, 
one in five adults over 15 years of age is obese in the OECD 
countries. Iceland is near the OECD average in the same 
report.20 We have previously analysed the trend in BMI 
in Iceland. According to the Icelandic Heart Association 
study, the mean BMI increased by 2 units in both genders 
(45–64 years old) from 1967 to 2007.21 However, in the 
OECD report, it is revealed that obesity has stabilised in 
England, Italy, Korea and Spain.20 Comparison with the 
Tromsø 6 study shows that the mean BMI was 0.9 units 
kg/m2 higher in women and 0.8 kg/m2 higher in men in 
the REFINE-Reykjavik study than in the Tromsø 6 study.
Almost a third of men aged 25–29 years smoked in the 
REFINE-Reykjavik study. This was somewhat lower than 
the average prevalence of smoking in developed coun-
tries according to a large international survey,22 where 
about 38% of men in this age group smoked in 2012. 
Smoking decreased with age and was down to 17% in 
the 65–69 year old group in the REFINE-Reykjavik study. 
Comparison between the REFINE-Reykjavik study and the 
Tromsø 6 study showed that smoking was somewhat more 
prevalent in both men and women in the Tromsø 6 study. 
In men, the difference was 4% (21% REFINE-Reykjavik 
vs 25% Tromsø 6) and 9% in women (20% REFINE-Reyk-
javik vs 29% in Tromsø 6). Prevalence of women smokers 
in the REFINE-Reykjavik was similar to the prevalence 
of smoking among men in the same age groups (21%). 
This was similar as was seen in the Tromsö 6 study where 
smoking was even more prevalent among women (29.2%) 
than among men (25.4%). This is different from what was 
seen in many other developed countries where smoking 
among women is approximately half of the prevalence of 
smoking in men.22
Blood pressure should be below 140/90 mm Hg 
according to the European Society of Cardiology (ESC) 
2012 guidelines. The mean values for blood pressure 
in the REFINE-Reykjavik study were well below the 
ESC targets for all age and gender groups. The mean 
blood pressure levels for men were 126/70 mm Hg and 
116/69 mm Hg for women. We have previously shown 
that blood pressure levels have been dropping in Iceland 
from 1967 to 2007 in middle-aged men and women by 
approximately 20 mm Hg,23 and this drop has been seen 
in all age groups, indicating a population effect rather 
than an effect of treatment with blood pressure-lowering 
drugs. However, the use of blood pressure-lowering 
drugs was very common in the REFINE-Reykjavik study 
in the oldest age groups. More than half of men and 
women in the age group of 65–69 years were taking blood 
pressure-lowering drugs. This high prevalence of drug 
use could lower the population mean in the oldest age 
groups. The blood pressure results in the REFINE-Reyk-
javik were 8 mm Hg lower in men (aged 40–69 years) and 
10 mm Hg lower in women than in the Tromsø 6 study. 
The difference was similar in each age group. Differ-
ence in the use of blood pressure-lowering drugs could 
add to this highly clinically significant difference. This 
difference is similar in magnitude as the decline in blood 
 o
n
 10 August 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019385 on 31 May 2018. Downloaded from 
8 Thorsson B, et al. BMJ Open 2018;8:e019385. doi:10.1136/bmjopen-2017-019385
Open Access 
pressure in women from 1978 to 2008 in the Tromsø 6 
study.24
According to the 2016 ESC guidelines for the manage-
ment of dyslipidaemia, drug treatment should be consid-
ered if the 10-year risk of fatal cardiovascular disease 
exceeds 1% and LDL cholesterol is between 2.6 mmol/L 
and <4.0 mmol/L despite of lifestyle intervention.25 Mean 
LDL cholesterol level in all age groups except in young 
women (25–29 years) was above this lower limit. The mean 
LDL cholesterol level was highest in 55–59 years men 
(3.4 mmol/L) and women 60–64 years (3.5 mmol/L). 
Comparison with the Tromsø 6 study revealed that in 
40–69 years old, the mean LDL cholesterol was 0.5 mmol/L 
lower in men (3.3 vs 3.8) and 0.3 mmol/L lower in 
women (3.3 vs 3.6) in the REFINE-Reykjavik study than in 
the Tromsø 6 study. This difference was 15% in men and 
11% in women. For comparison, the mean percentage 
lowering of LDL cholesterol after administrating 20 mg 
of simvastatin has been shown to be on average 35%.26 
In the REFINE-Reykjavik study, the LDL cholesterol was 
measured in participants after fasting from the evening 
before, whereas in the Tromsø 6 study, the LDL choles-
terol was measured in non-fasting participants. In the 
Copenhagen General Population Study, the levels of 
LDL cholesterol was 0.2 mmol/L lower after meal than 
after fasting so the difference in LDL level between the 
REFINE-Reykjavik study and Tromsø 6 study could be 
even larger.27
We have previously published that TC levels in Iceland 
have been dropping as in other developed countries for 
the last decades.28 The drop has been similar in both 
genders and all age groups. The mean drop in TC in the 
Icelandic population from 1967 to 2008 was 1.5 mmol/L 
in males and 1.6 mmol/L in females.28
The prevalence of diabetes has been historically been 
low in Iceland, but the prevalence of diabetes in men in the 
REFINE-Reykjavik study was almost identical to the preva-
lence of diabetes in men according to a population-based 
healthcare database in Sweden.29 Another recent Swedish 
study shows that prevalence of diabetes was 59.8 per 
1000 (6%) for men and 38.4 per 1000 (4%) for women 
40–64 years old in 2010.30 Comparison on the prevalence 
of type 2 diabetes in men between the REFINE-Reykjavik 
study and Tromsø 6 study also showed very similar results 
(7.4%). The prevalence was low in both studies among 
women (3.4% in REFINE-Reykjavik vs 4.9 in the Tromsø 
6 study). The prevalence of diabetes in Iceland, Norway 
or Sweden has been, from a global viewpoint, relatively 
low. The prevalence of diabetes in USA in people older 
than 20 years was for example, according to the NHANES 
study, 13.4% in men and 10.2% in women in 2007–2010.31
In conclusion, the mean CIMT was similar in the 
REFINE-Reykjavik study and the Tromsø 6 study. The 
higher prevalence of carotid plaque in the REFINE-Reyk-
javik study was probably due to differences in the defi-
nition of plaque between the two studies. However, the 
mean for systolic blood pressure and mean LDL choles-
terol levels were higher and smoking more prevalent in 
the Tromsø 6 study, but BMI was higher the REFINE-Reyk-
javik study.
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